Global Anti-Dermatomycosis Treatment Supply, Demand and Key Producers, 2023-2029
Page: 115
Published Date: 01 Sep 2023
Category: Medical Devices & Consumables
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The global Anti-Dermatomycosis Treatment market size is expected to reach $ 5992 million by 2029, rising at a market growth of 5.9% CAGR during the forecast period (2023-2029).
The global anti-dermatomycosis treatment market refers to the overall market for medications and therapies used in the treatment of dermatomycosis, which is a fungal infection of the skin. Dermatomycosis, also known as tinea or ringworm, can affect various parts of the body, including the scalp, body, groin, feet, and nails.
The market for anti-dermatomycosis treatment has been growing steadily due to factors such as the increasing prevalence of fungal infections, rising awareness, and the development of effective antifungal therapies. Dermatomycosis is a common condition, particularly in tropical and subtropical regions, and can affect individuals of all ages.
The market is segmented based on various factors, including product type, route of administration, distribution channel, and geography. Different types of anti-dermatomycosis treatments include topical antifungal creams, oral antifungal medications, and, in severe cases, intravenous antifungal therapies.
Topical antifungal creams are commonly used as first-line treatments for dermatomycosis and are available over the counter or by prescription. Oral antifungal medications, such as azoles, allylamines, and griseofulvin, are prescribed for more severe or widespread infections or those that do not respond to topical treatments. In some cases, combination therapy may be used to enhance efficacy.
The market is also influenced by the distribution channel, with anti-dermatomycosis treatments being available in retail pharmacies, hospital pharmacies, and online platforms. The choice of distribution channel may depend on factors such as the severity of the infection, prescription requirements, and consumer preferences.
Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific region, including countries like India and China, is expected to witness significant growth in the market due to a high burden of fungal infections and a large population.
Key factors driving the growth of the global anti-dermatomycosis treatment market include the increasing prevalence of fungal infections, the growing adoption of antifungal therapies, the development of novel treatment options, and the efforts of pharmaceutical companies to expand their product portfolios.
Key players in the market include pharmaceutical companies, biotechnology firms, and research organizations. These companies invest in research and development, clinical trials, and collaborations to develop new antifungal therapies and enhance existing treatment options.
Market dynamics, growth rates, and the competitive landscape may vary across regions and specific antifungal product types. Factors such as drug resistance, regulatory approvals, pricing, and reimbursement policies can influence the market dynamics.
In summary, the global anti-dermatomycosis treatment market is witnessing steady growth due to the increasing prevalence of fungal infections and the development of effective antifungal therapies. However, market conditions and growth rates may be influenced by factors like the emergence of drug-resistant strains, regulatory challenges, competitive landscape, and access to healthcare services.
Dermatomycosis are infections of skin, nails, and hair which are caused by dermatophytes, yeasts and moulds.Anti-fungals are grouped in to three classes based on action like azoles (inhibit synthesis of Ergosterol), Polyenes (membrane sterols), and 5-Fluorocytosine (inhibits macromolecular synthesis).
This report studies the global Anti-Dermatomycosis Treatment demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Anti-Dermatomycosis Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Anti-Dermatomycosis Treatment that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Anti-Dermatomycosis Treatment total market, 2018-2029, (USD Million)
Global Anti-Dermatomycosis Treatment total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Anti-Dermatomycosis Treatment total market, key domestic companies and share, (USD Million)
Global Anti-Dermatomycosis Treatment revenue by player and market share 2018-2023, (USD Million)
Global Anti-Dermatomycosis Treatment total market by Type, CAGR, 2018-2029, (USD Million)
Global Anti-Dermatomycosis Treatment total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Anti-Dermatomycosis Treatment market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc., Sanofi S.A., Novatis AG, Mylan N.V., Abbott Laboratories, Bayer AG, Eli Lilly and Company, AbbVie Inc. and Glaxosmithkline Plc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Anti-Dermatomycosis Treatment market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Anti-Dermatomycosis Treatment Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Anti-Dermatomycosis Treatment Market, Segmentation by Type
Polyens
Azoles
Allylamines
Echinocandins
Others
Global Anti-Dermatomycosis Treatment Market, Segmentation by Application
Tinea Corporis
Tinea Unguium
Aspergillosis
Tinea Capitis
Others
Companies Profiled:
Pfizer Inc.
Sanofi S.A.
Novatis AG
Mylan N.V.
Abbott Laboratories
Bayer AG
Eli Lilly and Company
AbbVie Inc.
Glaxosmithkline Plc
Janssen Pharmaceuticals, Inc.
Taro Pharmaceutical Industries Ltd.
Mayne Pharma Group Limited
Viamet Pharmaceuticals, Inc.
Scynexis Inc.
Enzon Pharmaceuticals
Gilead Sciences Inc.
Key Questions Answered
1. How big is the global Anti-Dermatomycosis Treatment market?
2. What is the demand of the global Anti-Dermatomycosis Treatment market?
3. What is the year over year growth of the global Anti-Dermatomycosis Treatment market?
4. What is the total value of the global Anti-Dermatomycosis Treatment market?
5. Who are the major players in the global Anti-Dermatomycosis Treatment market?
Table of Contents
1 Supply Summary
1.1 Anti-Dermatomycosis Treatment Introduction
1.2 World Anti-Dermatomycosis Treatment Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Anti-Dermatomycosis Treatment Total Market by Region (by Headquarter Location)
1.3.1 World Anti-Dermatomycosis Treatment Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Anti-Dermatomycosis Treatment Market Size (2018-2029)
1.3.3 China Anti-Dermatomycosis Treatment Market Size (2018-2029)
1.3.4 Europe Anti-Dermatomycosis Treatment Market Size (2018-2029)
1.3.5 Japan Anti-Dermatomycosis Treatment Market Size (2018-2029)
1.3.6 South Korea Anti-Dermatomycosis Treatment Market Size (2018-2029)
1.3.7 ASEAN Anti-Dermatomycosis Treatment Market Size (2018-2029)
1.3.8 India Anti-Dermatomycosis Treatment Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Anti-Dermatomycosis Treatment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Anti-Dermatomycosis Treatment Major Market Trends
2.1 World Anti-Dermatomycosis Treatment Consumption Value (2018-2029)
2.2 World Anti-Dermatomycosis Treatment Consumption Value by Region
2.2.1 World Anti-Dermatomycosis Treatment Consumption Value by Region (2018-2023)
2.2.2 World Anti-Dermatomycosis Treatment Consumption Value Forecast by Region (2024-2029)
2.3 United States Anti-Dermatomycosis Treatment Consumption Value (2018-2029)
2.4 China Anti-Dermatomycosis Treatment Consumption Value (2018-2029)
2.5 Europe Anti-Dermatomycosis Treatment Consumption Value (2018-2029)
2.6 Japan Anti-Dermatomycosis Treatment Consumption Value (2018-2029)
2.7 South Korea Anti-Dermatomycosis Treatment Consumption Value (2018-2029)
2.8 ASEAN Anti-Dermatomycosis Treatment Consumption Value (2018-2029)
2.9 India Anti-Dermatomycosis Treatment Consumption Value (2018-2029)
3.1 World Anti-Dermatomycosis Treatment Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Anti-Dermatomycosis Treatment Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Anti-Dermatomycosis Treatment in 2022
3.2.3 Global Concentration Ratios (CR8) for Anti-Dermatomycosis Treatment in 2022
3.3 Anti-Dermatomycosis Treatment Company Evaluation Quadrant
3.4 Anti-Dermatomycosis Treatment Market: Overall Company Footprint Analysis
3.4.1 Anti-Dermatomycosis Treatment Market: Region Footprint
3.4.2 Anti-Dermatomycosis Treatment Market: Company Product Type Footprint
3.4.3 Anti-Dermatomycosis Treatment Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4.1 United States VS China: Anti-Dermatomycosis Treatment Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Anti-Dermatomycosis Treatment Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Anti-Dermatomycosis Treatment Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Anti-Dermatomycosis Treatment Consumption Value Comparison
4.2.1 United States VS China: Anti-Dermatomycosis Treatment Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Anti-Dermatomycosis Treatment Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Anti-Dermatomycosis Treatment Companies and Market Share, 2018-2023
4.3.1 United States Based Anti-Dermatomycosis Treatment Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Anti-Dermatomycosis Treatment Revenue, (2018-2023)
4.4 China Based Companies Anti-Dermatomycosis Treatment Revenue and Market Share, 2018-2023
4.4.1 China Based Anti-Dermatomycosis Treatment Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Anti-Dermatomycosis Treatment Revenue, (2018-2023)
4.5 Rest of World Based Anti-Dermatomycosis Treatment Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Anti-Dermatomycosis Treatment Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Anti-Dermatomycosis Treatment Revenue, (2018-2023)
5.1 World Anti-Dermatomycosis Treatment Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Polyens
5.2.2 Azoles
5.2.3 Allylamines
5.2.4 Echinocandins
5.2.5 Others
5.3 Market Segment by Type
5.3.1 World Anti-Dermatomycosis Treatment Market Size by Type (2018-2023)
5.3.2 World Anti-Dermatomycosis Treatment Market Size by Type (2024-2029)
5.3.3 World Anti-Dermatomycosis Treatment Market Size Market Share by Type (2018-2029)
6.1 World Anti-Dermatomycosis Treatment Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Tinea Corporis
6.2.2 Tinea Unguium
6.2.3 Aspergillosis
6.2.4 Tinea Capitis
6.2.5 Tinea Capitis
6.3 Market Segment by Application
6.3.1 World Anti-Dermatomycosis Treatment Market Size by Application (2018-2023)
6.3.2 World Anti-Dermatomycosis Treatment Market Size by Application (2024-2029)
6.3.3 World Anti-Dermatomycosis Treatment Market Size by Application (2018-2029)
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Details
7.1.2 Pfizer Inc. Major Business
7.1.3 Pfizer Inc. Anti-Dermatomycosis Treatment Product and Services
7.1.4 Pfizer Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Pfizer Inc. Recent Developments/Updates
7.1.6 Pfizer Inc. Competitive Strengths & Weaknesses
7.2 Sanofi S.A.
7.2.1 Sanofi S.A. Details
7.2.2 Sanofi S.A. Major Business
7.2.3 Sanofi S.A. Anti-Dermatomycosis Treatment Product and Services
7.2.4 Sanofi S.A. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Sanofi S.A. Recent Developments/Updates
7.2.6 Sanofi S.A. Competitive Strengths & Weaknesses
7.3 Novatis AG
7.3.1 Novatis AG Details
7.3.2 Novatis AG Major Business
7.3.3 Novatis AG Anti-Dermatomycosis Treatment Product and Services
7.3.4 Novatis AG Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Novatis AG Recent Developments/Updates
7.3.6 Novatis AG Competitive Strengths & Weaknesses
7.4 Mylan N.V.
7.4.1 Mylan N.V. Details
7.4.2 Mylan N.V. Major Business
7.4.3 Mylan N.V. Anti-Dermatomycosis Treatment Product and Services
7.4.4 Mylan N.V. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Mylan N.V. Recent Developments/Updates
7.4.6 Mylan N.V. Competitive Strengths & Weaknesses
7.5 Abbott Laboratories
7.5.1 Abbott Laboratories Details
7.5.2 Abbott Laboratories Major Business
7.5.3 Abbott Laboratories Anti-Dermatomycosis Treatment Product and Services
7.5.4 Abbott Laboratories Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Abbott Laboratories Recent Developments/Updates
7.5.6 Abbott Laboratories Competitive Strengths & Weaknesses
7.6 Bayer AG
7.6.1 Bayer AG Details
7.6.2 Bayer AG Major Business
7.6.3 Bayer AG Anti-Dermatomycosis Treatment Product and Services
7.6.4 Bayer AG Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Bayer AG Recent Developments/Updates
7.6.6 Bayer AG Competitive Strengths & Weaknesses
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Details
7.7.2 Eli Lilly and Company Major Business
7.7.3 Eli Lilly and Company Anti-Dermatomycosis Treatment Product and Services
7.7.4 Eli Lilly and Company Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Eli Lilly and Company Recent Developments/Updates
7.7.6 Eli Lilly and Company Competitive Strengths & Weaknesses
7.8 AbbVie Inc.
7.8.1 AbbVie Inc. Details
7.8.2 AbbVie Inc. Major Business
7.8.3 AbbVie Inc. Anti-Dermatomycosis Treatment Product and Services
7.8.4 AbbVie Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 AbbVie Inc. Recent Developments/Updates
7.8.6 AbbVie Inc. Competitive Strengths & Weaknesses
7.9 Glaxosmithkline Plc
7.9.1 Glaxosmithkline Plc Details
7.9.2 Glaxosmithkline Plc Major Business
7.9.3 Glaxosmithkline Plc Anti-Dermatomycosis Treatment Product and Services
7.9.4 Glaxosmithkline Plc Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Glaxosmithkline Plc Recent Developments/Updates
7.9.6 Glaxosmithkline Plc Competitive Strengths & Weaknesses
7.10 Janssen Pharmaceuticals, Inc.
7.10.1 Janssen Pharmaceuticals, Inc. Details
7.10.2 Janssen Pharmaceuticals, Inc. Major Business
7.10.3 Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product and Services
7.10.4 Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Janssen Pharmaceuticals, Inc. Recent Developments/Updates
7.10.6 Janssen Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
7.11 Taro Pharmaceutical Industries Ltd.
7.11.1 Taro Pharmaceutical Industries Ltd. Details
7.11.2 Taro Pharmaceutical Industries Ltd. Major Business
7.11.3 Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Product and Services
7.11.4 Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Taro Pharmaceutical Industries Ltd. Recent Developments/Updates
7.11.6 Taro Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
7.12 Mayne Pharma Group Limited
7.12.1 Mayne Pharma Group Limited Details
7.12.2 Mayne Pharma Group Limited Major Business
7.12.3 Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Product and Services
7.12.4 Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Mayne Pharma Group Limited Recent Developments/Updates
7.12.6 Mayne Pharma Group Limited Competitive Strengths & Weaknesses
7.13 Viamet Pharmaceuticals, Inc.
7.13.1 Viamet Pharmaceuticals, Inc. Details
7.13.2 Viamet Pharmaceuticals, Inc. Major Business
7.13.3 Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product and Services
7.13.4 Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Viamet Pharmaceuticals, Inc. Recent Developments/Updates
7.13.6 Viamet Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
7.14 Scynexis Inc.
7.14.1 Scynexis Inc. Details
7.14.2 Scynexis Inc. Major Business
7.14.3 Scynexis Inc. Anti-Dermatomycosis Treatment Product and Services
7.14.4 Scynexis Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Scynexis Inc. Recent Developments/Updates
7.14.6 Scynexis Inc. Competitive Strengths & Weaknesses
7.15 Enzon Pharmaceuticals
7.15.1 Enzon Pharmaceuticals Details
7.15.2 Enzon Pharmaceuticals Major Business
7.15.3 Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Product and Services
7.15.4 Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Enzon Pharmaceuticals Recent Developments/Updates
7.15.6 Enzon Pharmaceuticals Competitive Strengths & Weaknesses
7.16 Gilead Sciences Inc.
7.16.1 Gilead Sciences Inc. Details
7.16.2 Gilead Sciences Inc. Major Business
7.16.3 Gilead Sciences Inc. Anti-Dermatomycosis Treatment Product and Services
7.16.4 Gilead Sciences Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Gilead Sciences Inc. Recent Developments/Updates
7.16.6 Gilead Sciences Inc. Competitive Strengths & Weaknesses
8.1 Anti-Dermatomycosis Treatment Industry Chain
8.2 Anti-Dermatomycosis Treatment Upstream Analysis
8.3 Anti-Dermatomycosis Treatment Midstream Analysis
8.4 Anti-Dermatomycosis Treatment Downstream Analysis
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Table of Figures
List of Tables
Table 1. World Anti-Dermatomycosis Treatment Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Anti-Dermatomycosis Treatment Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Anti-Dermatomycosis Treatment Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Anti-Dermatomycosis Treatment Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Anti-Dermatomycosis Treatment Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Anti-Dermatomycosis Treatment Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Anti-Dermatomycosis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Anti-Dermatomycosis Treatment Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Anti-Dermatomycosis Treatment Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Anti-Dermatomycosis Treatment Players in 2022
Table 12. World Anti-Dermatomycosis Treatment Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Anti-Dermatomycosis Treatment Company Evaluation Quadrant
Table 14. Head Office of Key Anti-Dermatomycosis Treatment Player
Table 15. Anti-Dermatomycosis Treatment Market: Company Product Type Footprint
Table 16. Anti-Dermatomycosis Treatment Market: Company Product Application Footprint
Table 17. Anti-Dermatomycosis Treatment Mergers & Acquisitions Activity
Table 18. United States VS China Anti-Dermatomycosis Treatment Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Anti-Dermatomycosis Treatment Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Anti-Dermatomycosis Treatment Companies, Headquarters (States, Country)
Table 21. United States Based Companies Anti-Dermatomycosis Treatment Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Anti-Dermatomycosis Treatment Revenue Market Share (2018-2023)
Table 23. China Based Anti-Dermatomycosis Treatment Companies, Headquarters (Province, Country)
Table 24. China Based Companies Anti-Dermatomycosis Treatment Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Anti-Dermatomycosis Treatment Revenue Market Share (2018-2023)
Table 26. Rest of World Based Anti-Dermatomycosis Treatment Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Anti-Dermatomycosis Treatment Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Anti-Dermatomycosis Treatment Revenue Market Share (2018-2023)
Table 29. World Anti-Dermatomycosis Treatment Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Anti-Dermatomycosis Treatment Market Size by Type (2018-2023) & (USD Million)
Table 31. World Anti-Dermatomycosis Treatment Market Size by Type (2024-2029) & (USD Million)
Table 32. World Anti-Dermatomycosis Treatment Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Anti-Dermatomycosis Treatment Market Size by Application (2018-2023) & (USD Million)
Table 34. World Anti-Dermatomycosis Treatment Market Size by Application (2024-2029) & (USD Million)
Table 35. Pfizer Inc. Basic Information, Area Served and Competitors
Table 36. Pfizer Inc. Major Business
Table 37. Pfizer Inc. Anti-Dermatomycosis Treatment Product and Services
Table 38. Pfizer Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Pfizer Inc. Recent Developments/Updates
Table 40. Pfizer Inc. Competitive Strengths & Weaknesses
Table 41. Sanofi S.A. Basic Information, Area Served and Competitors
Table 42. Sanofi S.A. Major Business
Table 43. Sanofi S.A. Anti-Dermatomycosis Treatment Product and Services
Table 44. Sanofi S.A. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Sanofi S.A. Recent Developments/Updates
Table 46. Sanofi S.A. Competitive Strengths & Weaknesses
Table 47. Novatis AG Basic Information, Area Served and Competitors
Table 48. Novatis AG Major Business
Table 49. Novatis AG Anti-Dermatomycosis Treatment Product and Services
Table 50. Novatis AG Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Novatis AG Recent Developments/Updates
Table 52. Novatis AG Competitive Strengths & Weaknesses
Table 53. Mylan N.V. Basic Information, Area Served and Competitors
Table 54. Mylan N.V. Major Business
Table 55. Mylan N.V. Anti-Dermatomycosis Treatment Product and Services
Table 56. Mylan N.V. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Mylan N.V. Recent Developments/Updates
Table 58. Mylan N.V. Competitive Strengths & Weaknesses
Table 59. Abbott Laboratories Basic Information, Area Served and Competitors
Table 60. Abbott Laboratories Major Business
Table 61. Abbott Laboratories Anti-Dermatomycosis Treatment Product and Services
Table 62. Abbott Laboratories Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Abbott Laboratories Recent Developments/Updates
Table 64. Abbott Laboratories Competitive Strengths & Weaknesses
Table 65. Bayer AG Basic Information, Area Served and Competitors
Table 66. Bayer AG Major Business
Table 67. Bayer AG Anti-Dermatomycosis Treatment Product and Services
Table 68. Bayer AG Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Bayer AG Recent Developments/Updates
Table 70. Bayer AG Competitive Strengths & Weaknesses
Table 71. Eli Lilly and Company Basic Information, Area Served and Competitors
Table 72. Eli Lilly and Company Major Business
Table 73. Eli Lilly and Company Anti-Dermatomycosis Treatment Product and Services
Table 74. Eli Lilly and Company Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Eli Lilly and Company Recent Developments/Updates
Table 76. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 77. AbbVie Inc. Basic Information, Area Served and Competitors
Table 78. AbbVie Inc. Major Business
Table 79. AbbVie Inc. Anti-Dermatomycosis Treatment Product and Services
Table 80. AbbVie Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. AbbVie Inc. Recent Developments/Updates
Table 82. AbbVie Inc. Competitive Strengths & Weaknesses
Table 83. Glaxosmithkline Plc Basic Information, Area Served and Competitors
Table 84. Glaxosmithkline Plc Major Business
Table 85. Glaxosmithkline Plc Anti-Dermatomycosis Treatment Product and Services
Table 86. Glaxosmithkline Plc Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Glaxosmithkline Plc Recent Developments/Updates
Table 88. Glaxosmithkline Plc Competitive Strengths & Weaknesses
Table 89. Janssen Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
Table 90. Janssen Pharmaceuticals, Inc. Major Business
Table 91. Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product and Services
Table 92. Janssen Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Janssen Pharmaceuticals, Inc. Recent Developments/Updates
Table 94. Janssen Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 95. Taro Pharmaceutical Industries Ltd. Basic Information, Area Served and Competitors
Table 96. Taro Pharmaceutical Industries Ltd. Major Business
Table 97. Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Product and Services
Table 98. Taro Pharmaceutical Industries Ltd. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Taro Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 100. Taro Pharmaceutical Industries Ltd. Competitive Strengths & Weaknesses
Table 101. Mayne Pharma Group Limited Basic Information, Area Served and Competitors
Table 102. Mayne Pharma Group Limited Major Business
Table 103. Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Product and Services
Table 104. Mayne Pharma Group Limited Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Mayne Pharma Group Limited Recent Developments/Updates
Table 106. Mayne Pharma Group Limited Competitive Strengths & Weaknesses
Table 107. Viamet Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
Table 108. Viamet Pharmaceuticals, Inc. Major Business
Table 109. Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Product and Services
Table 110. Viamet Pharmaceuticals, Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Viamet Pharmaceuticals, Inc. Recent Developments/Updates
Table 112. Viamet Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 113. Scynexis Inc. Basic Information, Area Served and Competitors
Table 114. Scynexis Inc. Major Business
Table 115. Scynexis Inc. Anti-Dermatomycosis Treatment Product and Services
Table 116. Scynexis Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Scynexis Inc. Recent Developments/Updates
Table 118. Scynexis Inc. Competitive Strengths & Weaknesses
Table 119. Enzon Pharmaceuticals Basic Information, Area Served and Competitors
Table 120. Enzon Pharmaceuticals Major Business
Table 121. Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Product and Services
Table 122. Enzon Pharmaceuticals Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Enzon Pharmaceuticals Recent Developments/Updates
Table 124. Gilead Sciences Inc. Basic Information, Area Served and Competitors
Table 125. Gilead Sciences Inc. Major Business
Table 126. Gilead Sciences Inc. Anti-Dermatomycosis Treatment Product and Services
Table 127. Gilead Sciences Inc. Anti-Dermatomycosis Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 128. Global Key Players of Anti-Dermatomycosis Treatment Upstream (Raw Materials)
Table 129. Anti-Dermatomycosis Treatment Typical Customers
List of Figure
Figure 1. Anti-Dermatomycosis Treatment Picture
Figure 2. World Anti-Dermatomycosis Treatment Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Anti-Dermatomycosis Treatment Total Market Size (2018-2029) & (USD Million)
Figure 4. World Anti-Dermatomycosis Treatment Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Anti-Dermatomycosis Treatment Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Anti-Dermatomycosis Treatment Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Anti-Dermatomycosis Treatment Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Anti-Dermatomycosis Treatment Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Anti-Dermatomycosis Treatment Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Anti-Dermatomycosis Treatment Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Anti-Dermatomycosis Treatment Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Anti-Dermatomycosis Treatment Revenue (2018-2029) & (USD Million)
Figure 13. Anti-Dermatomycosis Treatment Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Anti-Dermatomycosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 16. World Anti-Dermatomycosis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Anti-Dermatomycosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 18. China Anti-Dermatomycosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Anti-Dermatomycosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Anti-Dermatomycosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Anti-Dermatomycosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Anti-Dermatomycosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 23. India Anti-Dermatomycosis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Anti-Dermatomycosis Treatment by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Anti-Dermatomycosis Treatment Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Anti-Dermatomycosis Treatment Markets in 2022
Figure 27. United States VS China: Anti-Dermatomycosis Treatment Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Anti-Dermatomycosis Treatment Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Anti-Dermatomycosis Treatment Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Anti-Dermatomycosis Treatment Market Size Market Share by Type in 2022
Figure 31. Polyens
Figure 32. Azoles
Figure 33. Allylamines
Figure 34. Echinocandins
Figure 35. Others
Figure 36. World Anti-Dermatomycosis Treatment Market Size Market Share by Type (2018-2029)
Figure 37. World Anti-Dermatomycosis Treatment Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 38. World Anti-Dermatomycosis Treatment Market Size Market Share by Application in 2022
Figure 39. Tinea Corporis
Figure 40. Tinea Unguium
Figure 41. Aspergillosis
Figure 42. Tinea Capitis
Figure 43. Others
Figure 44. Anti-Dermatomycosis Treatment Industrial Chain
Figure 45. Methodology
Figure 46. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Pfizer Inc. Sanofi S.A. Novatis AG Mylan N.V. Abbott Laboratories Bayer AG Eli Lilly and Company AbbVie Inc. Glaxosmithkline Plc Janssen Pharmaceuticals, Inc. Taro Pharmaceutical Industries Ltd. Mayne Pharma Group Limited Viamet Pharmaceuticals, Inc. Scynexis Inc. Enzon Pharmaceuticals Gilead Sciences Inc.
Related Reports
01 Sep 2023
Medical Devices & Consumables
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
